12 lectures · 135 items
17 min
7 min
20 min
18 min
27 min
1 min
15 min
10 min
2 min
10 min
10 min
5 min
FIMMG National Congress Italy: strengthening dyslipidaemia management in primary care
The Pulse of Primary Care - EPCCS Summit 2026
Talking to Patients About Statins: Why Most Reported Symptoms Aren't Causal
GPcardio and ACC’s NCD Academy Join Forces to Strengthen Primary Care in Cardiovascular Disease Prevention
Sex Differences and Trends in Cardiovascular Risk Management: Insights from a Long-Term Primary Care Study
Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) in Primary care: A Systematic Review of Guidelines
Study on Cardiovascular Risk Factors and Primary Care Utilization in Spain
Global Insights from the INTERASPIRE Study: Mapping Lipoprotein(a) Prevalence in Coronary Heart Disease Across Six WHO Regions
Web app effective in determining access to statins without a prescription
Slides | Take home messages of EPCCS Guidance on 'Managing elevated lipids in primary care'
Lečenje povišenih lipida u primarnoj zdravstvenoj zaštiti (PZZ)
Managementul dislipidemiei în asistența medicală primară
Managing elevated lipids in primary careManaging elevated lipids and statins – the good, the bad and the ugly?
Slides | Lipid-lowering: the evidence, the guidelines, the clinical reality
Lipid Management: What do the guidelines say and what are the implications for primary care?In a prospective cohort study of 18,741 patients with type 2 diabetes on lipid-lowering therapy, elevated remnant cholesterol and hsCRP levels were each independently associated with a higher risk of…
the ANGPTL4 antibody MAR001 lowers triglycerides up to 45.5 percent more than placebo without worsening glucose, and a single CRISPR infusion against ANGPTL3 removes 63 percent of triglycerides in ten patients with severe hypertriglyceridaemia
Two early-phase lipid trials from LBS.05 at AHA 2026 (Monday 9 November). TYDAL-TIMI 78 Part A, presented by Michelle O'Donoghue (TIMI Study Group) and published simultaneously in NEJM: 235 adults…
pelacarsen lowers lipoprotein(a) by 86 percent in 423 Black and Hispanic Americans with cardiovascular disease, the same reduction that prevented no events in Lp(a)HORIZON
Presented in FS.12 at AHA 2026 (Monday 9 November) and published simultaneously in Circulation: Population Health and Outcomes. Lp(a)FRONTIERS EXPANSION, a US phase 3b randomised, double-blind…
pelacarsen lowers lipoprotein(a) by 78 percent but prevents no events, hazard ratio 1.02 in 8,322 patients over 4.7 years
Presented in LBS.01 at AHA 2026 (Saturday 7 November) and published simultaneously in NEJM, with the extended analyses in NEJM Evidence. Lp(a)HORIZON randomised 8,350 patients (8,322 analysed; mean…
Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibitor Trials.
A pooled analysis of phase 3 trials (BROADWAY/BROOKLYN) and an updated meta-analysis evaluated the impact of the CETP inhibitor obicetrapib on glycaemia and new-onset diabetes in 1,700 participants…
The 2025 VA/DoD clinical practice guideline on lipid management introduces updated cardiovascular risk assessment tools, including the PREVENT calculator, one-time lipoprotein(a) testing, and…
Modern Lipid Management for ASCVD Prevention in Primary Care.
This narrative review outlines the evolving landscape of lipid management for atherosclerotic cardiovascular disease (ASCVD) prevention in primary care and cardiology. Beyond traditional risk scores…
atorvastatin 40 mg in healthy adults over 70 prevents 30 percent of cardiovascular events but does not extend disability-free survival
The trial the primary-care question has waited for: 9,971 healthy Australians aged 70 and over (mean 74.7, 52 percent women) randomised to atorvastatin 40 mg or placebo, median follow-up 5.9 years…
evolocumab in the cath lab gets 82 percent of infarct patients to LDL target within a year, without a demonstrable clinical difference
International open-label phase 4 trial: 2,161 patients with high-risk acute MI undergoing PCI, evolocumab 140 mg every two weeks for one year with the first dose given before PCI, versus standard…
what STAREE will and will not answer
STAREE randomised almost 10,000 healthy Australians aged 70 and over to atorvastatin or placebo, with disability-free survival as its primary endpoint. Presented in Hot Line 2 at ESC Congress 2026…
target all atherogenic lipoproteins.
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in diabetes, partly driven by dyslipidaemia. Although LDL cholesterol (LDL-C) is the primary…
The combined value of lipoprotein(a) [Lp(a)] and high-sensitivity CRP (hsCRP) in primary prevention among people without standard modifiable risk factors (SMuRF-less: no smoking, obesity…